Table 1 Overview of the patients included in the study
Pt. no. | Gender | Age | Primary disease | BP used | Route | Location | treatment | Secondary intervention | Follow up (months) | Overall outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 62 | Breast cancer | Zoledronate | IV | Mand | SPO L-PRF | Yes—operated multiple times | 27 | Incomplete healing—exposed bone after 4 operations. No infection. |
2 | F | 54 | Breast cancer | Zoledronate | IV | Mand | SPO L-PRF | No | 14 | Complete healing |
3 | M | 80 | Prostate cancer | Zoledronate | IV | Mand | SPO L-PRF | No | 13 | Complete healing |
4 | M | 62 | Prostate cancer | Zoledronate | IV | Mand | MR L-PRF | No | 12 | Complete healing |
5 | M | 74 | Multiple myeloma | Zoledronate | IV | Mand | MR L-PRF | No | 12 | Complete healing |
6 | F | 77 | Osteoporosis | Alendronate | Oral | Mand | SPO L-PRF | No | 14 | Complete healing |
7 | F | 79 | Prostate cancer | Zoledronate | IV | Mand | MR L-PRF | No | 12 | Complete healing |
8 | M | 81 | Prostate cancer | Zoledronate | IV | Max | SPO L-PRF | No | 13 | Complete healing |
9 | F | 78 | Osteoporosis | Zoledronate | IV | Mand | SPO L-PRF | No | 15 | Complete healing |
10 | F | 54 | Breast cancer | Zoledronate | IV | Max | SPO L-PRF | Yes—OAF treated with flap surgery. | 79 | Incomplete healing—Partially resolved at 22 months of follow up. No infection. |
11 | M | 74 | Prostate cancer | Zoledronate | IV | Mand | SPO L-PRF | Yes, secondary intervention for sequestrectomy | 13 | Resolved after second intervention |
12 | F | 84 | Osteoporosis | Ibandronate, Zoledronate, Denosumab | Oral, IV, IV | Mand | Curettage L-PRF | Yes - operated multiple times. | 24 | Chronic fistula and pain were eliminated after third intervention. |
13 | M | 82 | Prostate cancer | Zoledronate | IV | Mand | SPO L-PRF | No | 13 | Complete healing |